Retinoid and related drugs
Drug Safety Update
January 2026: Isotretinoin – changes to prescribing guidance and additional risk minimisation measures
October 2025: Isotretinoin – updates to prescribing guidance and survey of services
October 2023: Isotretinoin (Roaccutane▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age
June 2019: Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
March 2019: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?
December 2014: Isotretinoin: risk of serious skin reactions.
December 2014: Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk
Oral isotretinoin (Roaccutane®) is a toxic and teratogenic drug and can only be prescribed by Consultant Dermatologists.
| Pack |
|---|
| 56 capsule |
| Pack |
|---|
| 30 capsule |
| Pack |
|---|
| 30 capsule |
| 56 capsule |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary